Clinical significance of STING expression and methylation in lung adenocarcinoma based on bioinformatics analysis

Zhou, Lin; Liu, Yu; Peng, Licong; Li, Jinping; Gan, Jinfeng

doi:10.1038/s41598-022-18278-6

Cited by 9 publications

(3 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mRNA profiles of 118 TCGA-TET patients were divided into MTA3 High and MTA3 Low groups according to the median expression value of MTA3 and then processed and analyzed by gene set enrichment analysis (GSEA) as previously described [ 9 , 38 ].…”

Section: Methodsmentioning

confidence: 99%

Prognostic and immunological significance of metastasis-associated protein 3 in patients with thymic epithelial tumors

Li,

Deng,

Liu

et al. 2024

Discov Onc

View full text Add to dashboard Cite

Background Immune checkpoint inhibitors have shown promising anticancer activity and have recently been proposed as a therapy for thymic epithelial tumors (TETs); however, this treatment is only effective for a subgroup of TET patients. Thus, this study aims to identify the potential genes implicated in the regulation of cancer immunity in TETs. Methods The TETs RNA-seq and clinical data were obtained from The Cancer Genome Atlas (TCGA) database. The clinical significance of the tumor microenvironment (TME) in TETs was evaluated. Weighted gene coexpression network analysis (WGCNA) was used to identify the immune response-related hub genes. The expression of metastasis-associated protein 3 (MTA3) in TETs was investigated in public datasets and a patient cohort. Kaplan‒Meier curves were generated to analyze the prognostic value of various factors. The Tumor Immune Estimation Resource (TIMER2.0) was used to estimate the relevance of MTA3 to immune cell infiltration. Gene set enrichment analysis (GSEA) and pathway enrichment analysis were applied to explore the MTA3-related pathways. Results The TME was found to be clinically significant in TETs. Moreover, MTA3 was identified as a key gene associated with the immune score, and lower MTA3 expression was linked to poor TME and reduced cytotoxic activity in TETs. Furthermore, MTA3 was found to be deregulated in TETs, predictive of poor prognosis. MTA3 was also significantly associated with the infiltration levels of various immune cell types and highly correlated with their corresponding markers. Notably, MTA3 was positively associated with various immune response pathways. Conclusion MTA3 is clinically significant in TETs and correlated with immune cell infiltration. Thus, MTA3 might be a biomarker for predicting the prognosis and immune status of TET patients.

show abstract

Section: Methodsmentioning

confidence: 99%

Prognostic and immunological significance of metastasis-associated protein 3 in patients with thymic epithelial tumors

Li,

Deng,

Liu

et al. 2024

Discov Onc

View full text Add to dashboard Cite

show abstract

“…Besides, An et al have found that negative correlation between the expression level of STING and its methylation level in NSCLC cells [ 35 ]. Conversely, a positive correlation has been observed between the level of STING methylation and poor prognosis in lung cancer [ 36 ]. It is reasonable to speculate that the expression of STING in cancer cell could lead to good prognosis for patients.…”

Section: Sting Plays a Dual Regulatory Role In Nsclc Tumor Cellsmentioning

confidence: 99%

Role of STING in the treatment of non-small cell lung cancer

Tang,

Zhou,

et al. 2024

Cell Commun Signal

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is a prevalent form of lung cancer. Patients with advanced NSCLC are currently being treated with various therapies, including traditional radiotherapy, chemotherapy, molecular targeted therapies and immunotherapy. However, a considerable proportion of advance patients who cannot benefit from them. Consequently, it is essential to identify a novel research target that offers an encouraging perspective. The stimulator of interferon genes (STING) has emerged as such a target. At present, it is confirmed that activating STING in NSCLC tumor cells can impede the proliferation and metastasis of dormant tumor cells. This review focuses on the role of STING in NSCLC treatment and the factors influencing its activation. Additionally, it explores the correlation between STING activation and diverse therapy modalities for NSCLC, such as radiotherapy, chemotherapy, molecular targeted therapies and immunotherapy. Furthermore, it proposes the prospect of innovative therapy methods involving nanoparticles, with the aim of using the features of STING to develop more strategies for NSCLC therapy.

show abstract

“…Another pivotal consideration is the expression of STING within tumor cells. Studies have revealed that STING expression is frequently downregulated in clinical cancer tissues, particularly in advanced tumor stages [ 32 , 33 ]. This diminishment in STING expression is often correlated with a poorer prognosis, as tumors exhibiting low STING expression tend to mount feeble responses to STING agonists, culminating in diminished therapeutic efficacy.…”

Section: Introductionmentioning

confidence: 99%

Mn-phenolic networks as synergistic carrier for STING agonists in tumor immunotherapy

Meng,

Huang,

Ding

et al. 2024

Materials Today Bio

View full text Add to dashboard Cite

Clinical significance of STING expression and methylation in lung adenocarcinoma based on bioinformatics analysis

Cited by 9 publications

References 55 publications

Prognostic and immunological significance of metastasis-associated protein 3 in patients with thymic epithelial tumors

Prognostic and immunological significance of metastasis-associated protein 3 in patients with thymic epithelial tumors

Role of STING in the treatment of non-small cell lung cancer

Mn-phenolic networks as synergistic carrier for STING agonists in tumor immunotherapy

Contact Info

Product

Resources

About